2.76
price up icon10.40%   0.26
after-market Handel nachbörslich: 2.75 -0.010 -0.36%
loading
Schlusskurs vom Vortag:
$2.50
Offen:
$2.55
24-Stunden-Volumen:
23,095
Relative Volume:
1.14
Marktkapitalisierung:
$4.25M
Einnahmen:
$8.62M
Nettoeinkommen (Verlust:
$-6.15M
KGV:
-0.2502
EPS:
-11.03
Netto-Cashflow:
$-5.32M
1W Leistung:
-0.54%
1M Leistung:
-26.59%
6M Leistung:
-43.67%
1J Leistung:
-59.00%
1-Tages-Spanne:
Value
$2.535
$2.837
1-Wochen-Bereich:
Value
$2.46
$2.8872
52-Wochen-Spanne:
Value
$1.94
$12.32

Evoke Pharma Inc Stock (EVOK) Company Profile

Name
Firmenname
Evoke Pharma Inc
Name
Telefon
858-345-1494
Name
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Name
Mitarbeiter
3
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
EVOK's Discussions on Twitter

Vergleichen Sie EVOK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
EVOK
Evoke Pharma Inc
2.76 4.25M 8.62M -6.15M -5.32M -11.03
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
22.95 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.77 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.49 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.08 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.09 20.17B 16.54B -1.64B 749.00M -1.45

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-06-22 Hochstufung H.C. Wainwright Neutral → Buy
2019-03-05 Herabstufung H.C. Wainwright Buy → Neutral
2018-03-08 Bestätigt B. Riley FBR, Inc. Buy
2017-10-19 Fortgesetzt FBR & Co. Buy
2017-03-16 Bestätigt Rodman & Renshaw Buy
2017-01-30 Hochstufung Laidlaw Neutral → Buy
2017-01-05 Hochstufung Rodman & Renshaw Neutral → Buy
2016-12-23 Bestätigt Rodman & Renshaw Neutral
2016-07-19 Bestätigt FBR Capital Outperform
2016-07-19 Herabstufung Noble Financial Buy → Hold
2016-07-18 Herabstufung Rodman & Renshaw Buy → Neutral
2016-03-16 Eingeleitet Northland Capital Outperform
2016-03-14 Bestätigt Ascendiant Capital Markets Buy
2016-02-17 Fortgesetzt FBR Capital Outperform
2014-12-03 Bestätigt MLV & Co Buy
2014-11-07 Eingeleitet MLV & Co Buy
2014-04-22 Eingeleitet Laidlaw Buy
2013-11-19 Eingeleitet Aegis Capital Buy
Alle ansehen

Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten

pulisher
Jun 18, 2025

Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World

Jun 18, 2025
pulisher
Jun 14, 2025

Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance

Jun 14, 2025
pulisher
Jun 11, 2025

Gastroparesis Treatment Market Booming Worldwide with - openPR.com

Jun 11, 2025
pulisher
Jun 05, 2025

Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com

Jun 05, 2025
pulisher
May 27, 2025

Geriatric Medicines Market Expands Globally with Aging - openPR.com

May 27, 2025
pulisher
May 26, 2025

Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com

May 26, 2025
pulisher
May 23, 2025

Global Geriatric Medicines Market Generated Opportunities, - openPR.com

May 23, 2025
pulisher
May 22, 2025

Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com

May 22, 2025
pulisher
May 15, 2025

Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World

May 15, 2025
pulisher
May 15, 2025

Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World

May 15, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

May 15, 2025
pulisher
May 15, 2025

Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks

May 15, 2025
pulisher
May 14, 2025

Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq

May 13, 2025
pulisher
May 11, 2025

Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 07, 2025

Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World

May 07, 2025
pulisher
Apr 29, 2025

StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech

Apr 25, 2025
pulisher
Apr 19, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - Yahoo Finance

Apr 17, 2025
pulisher
Apr 15, 2025

Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech

Apr 15, 2025
pulisher
Apr 09, 2025

Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India

Apr 09, 2025
pulisher
Apr 07, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN

Apr 07, 2025
pulisher
Apr 05, 2025

StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal

Apr 04, 2025
pulisher
Apr 04, 2025

Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest

Apr 04, 2025
pulisher
Apr 03, 2025

Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com

Apr 03, 2025
pulisher
Apr 02, 2025

Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India

Apr 02, 2025
pulisher
Apr 01, 2025

Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World

Apr 01, 2025

Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$13.51
price up icon 1.20%
$8.95
price up icon 1.13%
$128.18
price up icon 1.89%
$289.94
price up icon 1.24%
drug_manufacturers_specialty_generic RDY
$15.59
price up icon 1.83%
$17.09
price up icon 0.71%
Kapitalisierung:     |  Volumen (24h):